Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis

Current Medical Research and Opinion

Volumn 21, Issue 2, 2005, Pages 245-254

  Gotfried, Mark ^a,c   Notario, Gerard ^b   Spiller, Joy ^b   Palmer, Robert ^b   Busman, Todd ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Pulmonary Associates   (United States)

Author keywords

Acute bacterial exacerbation; Chronic bronchitis; Clarithromycin; Extended release

Indexed keywords

CLARITHROMYCIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; EXTENDED DRUG RELEASE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TASTE DISORDER; VOMITING;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; CLARITHROMYCIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 16344394031     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X26243     Document Type: Conference Paper

References (44)

1. National Institutes of Health, NHLBI. Morbidity and mortality: 2004 chart book on cardiovascular, lung, and blood diseases. Available from URL: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm [accessed November 2004]
2. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
3. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380S-385S
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
5. Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002;96:39-51
6. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190-209
7. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997;112(Suppl 6):310S-313S
8. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. J Am Med Assoc 1995;273:957-60
9. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JL, Blacklow NR, editors. Infectious diseases. Philadelphia (PA): W.B. Saunders Co; 1992. p. 476-85
10. Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Resp Infect 2000;15:59-70
11. Lorenz J. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis. Chemotherapy 1998;44(Suppl 1):15-8
12. Langan C, Clecner B, Cazzola CM, Brambilla C, Holmes CY, Staley H. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int J Clin Prac 1998;52:289-97
13. McCarty JM, Pierce PF. Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis. Ann Allergy Asthma Immunol 2001;87:327-34
14. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P, The Bronchitis Study Group. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Intern Med Res 2001;29:314-28
15. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D, The Bronchitis Study Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000;94:18-27
16. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000;94:1029-37
17. Paster RZ, McAdoo MA, Keyserling CH, Nemeth MA, Tack KJ, Griffin TJ. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis. Int J Cln Prac 2000;54:293-9
18. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis [The 070 Clinical Study group]. J Chemother 2002;12:314-25
19. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001;18:503-12
20. Fogarty CM, Bettis RB, Griffin TJ, Keyserling CH, Nemeth MA, Tack KJ. Comparison of a 5-day regimen of cefdinir with a 10-day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:851-8
21. Wilson R, Schentag JJ, Ball P, Mandell L, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52
22. Langan CE, Zuck P, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515-23
23. Nalepa P, Dobryniewska M, Busman T, Notario G. Short-course therapy of acute exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 2003;19:411-20
24. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. J Am Med Assoc 1998;279:365-70
25. Reyes H, Guiscafre H, Munoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory tract infections and acute diarrhea. J Clin Epidemiol 1997;50:1297-304
26. Weiss K, Vanjaka A, Canadian Study Group on Bronchitis. An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther 2002;24:2105-22
27. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-64
28. Guay DRP, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566-77
29. Adler JL, Jannetti W, Schneider D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 2000;22:1410-20
30. Adam D, Glaser-Caldow E, Wachter J, et al. Comparative efficacy of clarithromycin modified-release and clarithromycin immediate-release formulations in the treatment of lower respiratory tract infections. Clin Ther 2001;23:585-95
31. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved Standard NCCLS Document M7-A5 and 10th Informational Supplement: M100-S10 (M7); 2000
32. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 7th ed. Approved Standard NCCLS Document M2-A7 and 10th Informational Supplement: M100-S10 (M2); 2000
33. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolan R, editors. Principles and practice of infectious diseases, 5th ed. New York: Churchill Livingstone; 2000:706-10
34. Chodosh S, Schreurs A, Siami G, et al.; the Bronchitis Study Group. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8
35. Ziering W, McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998;26:68-75
36. DeAbate CA, Myers D, Henry D, et al. Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Drug Invest 1999;17:21-31
37. Langan CE, Zuck P, Vogel F, et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:515-23
38. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13
39. Lipsky BA, Unowsky J, Zhang H, Townsend L, Talbot GH. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy, sparfloxacin versus clarithromycin. Clin Ther 1999;21:954-65
40. Allin D, James I, Zachariah J, et al. Comparison of once- and twice-daily clarithromycin in the treatment of adults with severe acute lower respiratory tract infections. Clin Ther 2001;23:1958-68
41. Anzueto A, Fisher CL, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther 2001;23:72-86
42. Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001;23:97-107
43. Martinot JB, Carr WD, Cullen S, et al.; The Clarithromycin Once-a-Day Study Group. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther 2001;18:1-11
44. Anzueto A, Morris S. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int J Antimicrob Agents 2004;24:1-17